Swiss National Bank Puma Biotechnology, Inc. Transaction History

Swiss National Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$2.85 - $6.58 $189,610 - $437,767	-66,530 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$8.98 - $11.6 $83,514 - $107,880	-9,300 Reduced 12.26%	66,530 $611,000
Q3 2020 Nov 09, 2020	BUY	$9.5 - $11.14 $18,050 - $21,166	1,900 Added 2.57%	75,830 $765,000
Q2 2020 Aug 05, 2020	BUY	$7.01 - $13.24 $100,944 - $190,656	14,400 Added 24.19%	73,930 $771,000
Q4 2019 Feb 06, 2020	BUY	$6.5 - $10.73 $18,200 - $30,044	2,800 Added 4.94%	59,530 $521,000
Q2 2019 Aug 02, 2019	BUY	$12.3 - $35.76 $13,530 - $39,336	1,100 Added 1.98%	56,730 $722,000
Q1 2019 May 10, 2019	BUY	$20.77 - $42.37 $37,386 - $76,266	1,800 Added 3.34%	55,630 $2.15 Million
Q4 2018 Feb 13, 2019	BUY	$20.07 - $46.7 $38,133 - $88,730	1,900 Added 3.66%	53,830 $1.09 Million
Q1 2018 May 04, 2018	BUY	$59.7 - $99.25 $71,640 - $119,100	1,200 Added 2.37%	51,930 $3.53 Million
Q4 2017 Feb 07, 2018	BUY	$93.85 - $132.45 $159,545 - $225,164	1,700 Added 3.47%	50,730 $5.02 Million
Q3 2017 Nov 03, 2017	BUY	$72.0 - $119.75 $3.53 Million - $5.87 Million	49,030	49,030 $5.87 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.